A recent large trial suggested mortality benefits of tocilizumab in some groups of hospitalized patients7, consistent with a previous Mendelian randomization (MR) study suggesting IL-6 blockade might be helpful in COVID-19 hospitalization (Bovijn et al., 2020). This evidence concerns the gene IL6 and COVID-19.